DAB2, DAB adaptor protein 2, 1601

N. diseases: 107; N. variants: 11
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE Disabled-2 (DAB2) has been shown to be downregulated in a variety of human cancer types including breast tumors. 29247596 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 AlteredExpression group BEFREE Dab2 is expressed at variable level in meningiomas with different grade of malignancy and probably plays a pivotal role in the early stage of oncogenesis of malignant meningiomas. 24608456 2014
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE Generally considered as a tumor-suppressor gene, Dab2 may actually promote tumor progression in advanced cancers through epithelial-to-mesenchymal transition (EMT). 21725366 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 PosttranslationalModification group BEFREE This is the first study demonstrating frequent DAB2 promoter hypermethylation in human cancer. 20525238 2010
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 Biomarker group BEFREE The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. 16267015 2005
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 AlteredExpression group BEFREE In both nontumorigenic human ovarian surface epithelial and cancer cell lines, collagen IV, laminin, and Dab2 are expressed aberrantly. 12365030 2002
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 AlteredExpression group BEFREE It is believed that loss of DOC-2/hDab-2 expression is one of the early events of ovarian malignancy. 11687976 2001
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.080 AlteredExpression group BEFREE Thus, this study indicates that the loss of Dab2 expression is correlated with tumorigenicity of the cells disregarding the grade of the tumors, and loss of Dab2 expression is an early event in ovarian malignancies. 10340382 1999